Back to Journals » OncoTargets and Therapy » Volume 11

Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases

Authors Cheng Y, Zhang J, Geng HY, Qin SK, Hua HQ

Received 26 November 2017

Accepted for publication 22 February 2018

Published 6 April 2018 Volume 2018:11 Pages 1989—1995

DOI https://doi.org/10.2147/OTT.S158141

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang


Yuan Cheng, Juan Zhang, Haiyun Geng, Shukui Qin, Haiqing Hua

Department of Medical Oncology, People’s Liberation Army Cancer Center, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, Nanjing, China

Abstract: The aim of this study was to observe the efficacy and safety of apatinib combined with toptecan therapy in the multiline treatment of platinum-resistant recurrent ovarian cancer patients. The clinical records of three patients with platinum-resistant recurrent ovarian cancer treated with apatinib combined with toptecan therapy were analyzed and followed up for 3 months, and the related literatures were reviewed. The three patients achieved partial response and the tumor marker CA125 levels decreased significantly as an outcome of the treatment. Major adverse reactions were hypertension, hand–foot skin reaction, and anemia, which were manageable with medication. Apatinib combined with toptecan multiline therapy in the treatment of platinum-resistant recurrent ovarian cancer patients is effective, and the adverse effects are tolerated. Large-scale studies should be conducted to further determine the efficacy and safety of this treatment protocol.

Keywords: ovarian cancer, apatinib, topotecan, gynecological oncology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]